Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Immunomodulator Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The immunomodulator market has experienced significant growth over recent years. It is projected to expand from $237.02 billion in 2025 to $255.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.7%. This past expansion can be linked to several factors, including the increasing prevalence of autoimmune conditions, the widening scope of oncology and transplant procedures, the enhanced application of corticosteroids and traditional immunosuppressants, the growing integration of hospital-based immunotherapy, and a deeper clinical understanding of immune pathways.
The immunomodulator market size is projected to experience substantial growth in the coming years. It is expected to expand to $327.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is attributable to the development of innovative biologics and small molecule agents, increasing demand for immuno-oncology therapies, a greater emphasis on targeted and safer immunomodulators, the expansion of home-based and outpatient treatments, and broadening applications in emerging infectious and inflammatory diseases. Prominent trends within the forecast period include the increasing adoption of biologic and targeted immunotherapies, a growing reliance on combination immunomodulatory treatments, an elevated focus on personalized and precision immunotherapy, the wider application of immunomodulators in chronic and autoimmune diseases, and a noticeable shift towards outpatient and long-term immune management.
Get A Free Sample Report With In-Depth Market Insights:
Immunomodulator Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
An increase in chronic illnesses is projected to boost the expansion of the immunomodulator market. These are enduring health conditions that usually emerge slowly and persist for significant durations, frequently spanning years or an entire lifespan. Their increasing prevalence is linked to various interacting factors, including an aging global populace, lifestyle choices, genetic susceptibilities, and the availability and structure of healthcare services. Immunomodulators offer crucial treatment alternatives for addressing chronic conditions by adjusting immune reactions, decreasing inflammation, averting organ rejection, boosting immune monitoring, and enhancing symptom management. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported 41 million global deaths annually attributable to non-communicable diseases (NCDs) or chronic diseases, representing 74% of total deaths. Among these, 17.9 million deaths stemmed from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory conditions, and 2.0 million from diabetes. Consequently, the growing incidence of chronic diseases is propelling the expansion of the immunomodulator market.
Immunomodulator Market Segment Analysis And Revenue Potential
The immunomodulator market covered in this report is segmented –
1) By Product Type: Immunosuppressants, Immunostimulants, Other Product Types
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Oncology, Respiratory, Human Immunodeficiency Virus, Other Applications
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Immunosuppressants: Corticosteroids, Calcineurin Inhibitors (Tacrolimus, Cyclosporine), Mtor Inhibitors (Sirolimus, Everolimus), Antimetabolites ( Azathioprine, Methotrexate), Biologic Immunosuppressants (Monoclonal Antibodies Like Rituximab), Janus Kinase (Jak) Inhibitors, T-Cell Inhibitors, Other Immunosuppressive Agents
2) By Immunostimulants: Cytokine And Growth Factor-Based Immunostimulants ( Interferons, Interleukins), Monoclonal Antibodies For Immune Stimulation, Vaccines ( Cancer Vaccines, Preventive Vaccines), Adjuvants And Immune Modulatory Agents, Immunostimulatory Agents For Autoimmune Diseases, Toll-Like Receptor (Tlr) Agonists, Nucleic Acid-Based Immunostimulants ( Dna Or Rna Vaccines)
3) By Other Product Types: Biologics ( Fusion Proteins, Immune Checkpoint Inhibitors), Small Molecule Immunomodulators, Immunotherapy Drugs, Stem Cell-Based Immunomodulators, Immuno-Oncology Drugs, Probiotics And Other Natural Immunomodulatory Agents
Immunomodulator Market Innovation Trends Shaping Future Development
Major companies operating in the immunomodulator market are focusing on the creation of non-immunosuppressive products. This effort aims to meet the growing demand for therapies that provide targeted immune modulation without negatively impacting the body’s general immune function. Non-immunosuppressive refers to treatments or substances that do not suppress or diminish the immune system’s response. For instance, in February 2024, Nuvig Therapeutics, Inc., a US-based biotechnology company, started early-stage clinical trials for NVG-2089, a next-generation immune modulator. NVG-2089 is a proprietary product intended for patients with inflammatory myopathies and severe dermatologic autoimmune diseases. The FDA has granted fast-track designation for NVG-2089’s development for bullous pemphigoid. This novel, recombinant, non-immunosuppressive immunomodulator works by targeting type II Fc receptors to activate an endogenous regulatory mechanism that lessens autoimmune dysregulation. The primary goal of the study is to evaluate the safety and tolerability of NVG-2089, with secondary objectives examining its pharmacokinetics and pharmacodynamics.
Immunomodulator Market Key Players Shaping Industry Direction
Major companies operating in the immunomodulator market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Horizon Therapeutics plc, Incyte Corporation, Kyowa Kirin Co. Ltd.
View The Full Immunomodulator Market Report:
Immunomodulator Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the immunomodulator market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunomodulator market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
